| Previous close | N/A |
| Open | N/A |
| Bid | N/A x N/A |
| Ask | N/A x N/A |
| Day's range | N/A - N/A |
| 52-week range | undefined - undefined |
| Volume | |
| Avg. volume | N/A |
| Market cap | N/A |
| Beta (5Y monthly) | N/A |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.3500 |
| Earnings date | 25 July 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 1.71 |
GlobeNewswireHigher cantonal composition authority approved the amendments to the terms of the 2024 convertible bonds
Ad hoc announcement pursuant to Art. 53 LR Allschwil, Switzerland – June 25, 2024 Idorsia Ltd (SIX: IDIA) today announced that the hearing by the higher cantonal composition authority (obere kantonale Nachlassbehörde) (the Court) in relation to its outstanding convertible bonds originally maturing on July 17, 2024 (ISIN: CH0426820350) (the Bonds), was held today and that the Court approved the amendments of the Bond terms decided at the bondholder meeting held on May 6, 2024. Idorsia will announ
- GlobeNewswire
Idorsia’s novel treatment for chronic insomnia wins the prestigious Prix Galien Suisse 2024 innovation award in the ‘Primary & Speciality’ category
Idorsia’s dual orexin receptor antagonist, a drug working by a new mechanism of action for the treatment of chronic insomnia, has been awarded the prestigious Prix Galien Suisse 2024 innovation prize in the category ‘Primary & Speciality’.Each year, the Prix Galien Suisse honors the most innovative new medicines and diagnostics on the Swiss market. Allschwil, Switzerland – June 21, 2024Idorsia Ltd (SIX: IDIA) announced today that its novel treatment for chronic insomnia has been awarded the pres
- GlobeNewswire
Idorsia holds its Annual General Meeting of Shareholders
All Board proposals approved by the shareholders Allschwil, Switzerland – June 13, 2024At today’s Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted in favor of all proposals by the Board of Directors with very large majorities. The meeting was attended by 201 shareholders, representing a total of 90,297,668 shares, or 47.78% of the total outstanding shares. Led by the Chairman of the Board, Mathieu Simon, and Jean-Paul Clozel, who was the Chie
